Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Explorer3: Concizumab in Haemophilia A
NCT02490787Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2015
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 1, randomised, double-blind trial in hemophilia A comparing Concizumab with Placebo (2 arms). Primary endpoint: Number of adverse events (AEs) at 11 weeks. Started Sep 2015; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02490787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490787.